SCHEMBL2165092

SCHEMBL2165092

CSc1[nH]ncc1-c1nc2ccccc2s1

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ILK Q13418 12/20 0.68
▸ KDM4E B2RXH2 6/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ MAPT P10636 4/20 0.53
▸ ALDH1A1 P00352 4/20 0.53
▸ POLB P06746 2/20 0.53
▸ LMNA P02545 1/20 0.53
▸ HPGD P15428 1/20 0.53
▸ NPC1 O15118 3/20 0.51
▸ RAB9A P51151 3/20 0.51
▸ MEN1 O00255 2/20 0.51
▸ GAA P10253 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ L3MBTL1 Q9Y468 2/20 0.51
▸ TDP1 Q9NUW8 1/20 0.51
▸ HCRTR1 O43613 1/20 0.46
▸ GLA P06280 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL687627 0.78 ILK (1.00) ILKKDM4ESMN1; SMN2MAPTALDH1A1
SCHEMBL2165278 0.77 ILK (1.00) ILKKDM4ESMN1; SMN2MAPTALDH1A1
SCHEMBL2165274 0.74 ILK (1.00) ILKKDM4ESMN1; SMN2MAPTALDH1A1
SCHEMBL31038145 0.74 KDM4E (0.63) ILKKDM4ESMN1; SMN2MAPTALDH1A1
SCHEMBL687153 0.72 ILK (0.69) ILK
SCHEMBL231307 0.72 KDM4E (0.75) ILKKDM4ESMN1; SMN2MAPTALDH1A1
SCHEMBL2165289 0.71 ILK (0.59) ILKKDM4ESMN1; SMN2MAPTALDH1A1
SCHEMBL12854008 0.70 KDM4E (0.72) ILKKDM4ESMN1; SMN2MAPTALDH1A1
SCHEMBL827403 0.70 RAB9A (0.67) ILKKDM4ESMN1; SMN2MAPTALDH1A1
SCHEMBL22672257 0.69 ILK (1.00) ILKKDM4ESMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8754233-B2 Pyrazolylbenzothiazole derivatives and their use as therapeutic agents DERMIRA (CANADA), INC. (US) 2014-06-17 — — US disclosed
US-20130237572-A1 PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS DERMIRA (CANADA), INC. (US) 2013-09-12 — — US disclosed
US-20110178126-A1 PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS Valocor Therapeutics, Inc. (CA) 2011-07-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178126-A1 PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS REN, PGF, PKD1 ILK 1603/4885KDM4E 1780/4885SMN1; SMN2 4082/4885
US-20130237572-A1 PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS COXFA4L2, TYR, XDH ILK 4705/4885KDM4E 3729/4885SMN1; SMN2 4700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback